Amcinonide (Page 2 of 2)
OVERDOSAGE
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
DOSAGE AND ADMINISTRATION
Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.
Occlusive dressings may be a valuable therapeutic adjunct for the management of psoriasis or recalcitrant conditions.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
HOW SUPPLIED
Amcinonide Cream USP, 0.1% (1 mg/g) is supplied as follows:
- NDC 0168-0278-15 15 gram tubes
- NDC 0168-0278-30 30 gram tubes
- NDC 0168-0278-60 60 gram tubes
Store at 20°C to 25°C (68°F to 77°F),excursions permitted 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature]. DO NOT FREEZE.
E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747
46260501A
R03/2020
#53
PACKAGE LABEL — PRINCIPAL DISPLAY PANEL — 15 GRAM TUBE
- NDC 0168-0278-15
Fougera ®
AMCINONIDE
CREAM USP, 0.1%
Rx Only
NOT FOR OPHTHALMIC USE.
FOR DERMATOLOGIC USE ONLY.
NET WT 15 grams
PACKAGE LABEL — PRINCIPAL DISPLAY PANEL — 15 GRAM CARTON
- NDC 0168-0278-15
Rx Only
Fougera ®
AMCINONIDE
CREAM USP, 0.1%
NOT FOR OPHTHALMIC USE.
FOR DERMATOLOGIC USE ONLY.
- WARNING: Keep out of
reach of children.
NET WT 15 grams
AMCINONIDE amcinonide cream | |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||
|
Labeler — Fougera Pharmaceuticals Inc. (043838424) |
Revised: 06/2022 Fougera Pharmaceuticals Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.